0001209191-21-043537.txt : 20210628
0001209191-21-043537.hdr.sgml : 20210628
20210628182304
ACCESSION NUMBER: 0001209191-21-043537
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210624
FILED AS OF DATE: 20210628
DATE AS OF CHANGE: 20210628
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ferra Joseph J Jr
CENTRAL INDEX KEY: 0001733790
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40523
FILM NUMBER: 211054996
MAIL ADDRESS:
STREET 1: C/O SYROS PHARMACEUTICALS, INC.
STREET 2: 620 MEMORIAL DRIVE, SUITE 300
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Elevation Oncology, Inc.
CENTRAL INDEX KEY: 0001783032
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 841771427
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 888 SEVENTH AVE
STREET 2: 12TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10106
BUSINESS PHONE: 212-651-6380
MAIL ADDRESS:
STREET 1: 888 SEVENTH AVE
STREET 2: 12TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10106
FORMER COMPANY:
FORMER CONFORMED NAME: 14ner Oncology, Inc.
DATE OF NAME CHANGE: 20190719
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-06-24
0
0001783032
Elevation Oncology, Inc.
ELEV
0001733790
Ferra Joseph J Jr
C/O ELEVATION ONCOLOGY, INC.
888 SEVENTH AVENUE, 12TH FLOOR
NEW YORK
NY
10106
0
1
0
0
Chief Financial Officer
Stock Option (Right to Buy)
16.00
2021-06-24
4
A
0
249104
0.00
A
2031-06-23
Common Stock
249104
249104
D
Restricted Stock Unit (RSU)
2021-06-24
4
A
0
200995
0.00
A
Common Stock
200995
200995
D
25% of the total shares will vest on June 16, 2022, and the remainder will vest as to 1/48 of the total award in monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration.
25% of the RSUs will vest on June 16, 2022, and the remainder will vest in quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.
/s/ Shawn Leland, Attorney-in-Fact
2021-06-28